Celerion Recruits Participants for Anaphylaxis Treatment Study in Phoenix

Celerion is recruiting healthy male and female participants for a clinical research study in Phoenix focused on a marketed medication used in the emergency treatment of allergic reactions including anaphylaxis.

The study, identified by the code CA53926-1, involves a Phase 1 clinical trial. This stage of research typically focuses on evaluating the safety and dosage of a medication in humans.

Participants in the Phoenix-based study will undergo several scheduled check-ins and return visits throughout late November and December 2026. These sessions are designed to monitor the physiological effects of the treatment in a controlled environment.

The research schedule requires participants to be available for multiple site visits in Phoenix. The initial check-in period is set for Sunday, November 29, through Monday, November 30, 2026. The study includes two distinct phases of check-ins to gather longitudinal data.

The second round of check-ins is scheduled to begin on Sunday, December 13, and conclude on Monday, December 14, 2026. Following these observation periods, participants must return to the Phoenix site on Monday, December 28, 2026, to complete the study requirements.

Event Type	Start Date	End Date	Location
Phase 1 Check-In	November 29, 2026	November 30, 2026	Phoenix
Phase 2 Check-In	December 13, 2026	December 14, 2026	Phoenix
Return Visit	December 28, 2026	December 28, 2026	Phoenix

Those participating in the clinical study may receive a stipend. The specific amount of the payment is not fixed but may pay up to a reflected amount provided during the enrollment process. This compensation is intended to offset the time and travel required for the multiple visits in Phoenix.

The study aims to contribute to broader medical knowledge regarding the management of anaphylaxis. Clinical trials of this nature are essential for ensuring that emergency medications remain effective and safe for the general population during life-threatening allergic events.

Interested individuals can seek more information by calling 1-866-445-7033 in the United States. For those inquiring from the United Kingdom, the contact number is 02890 554000.